Valuation: Axonics, Inc.

Market Cap 3.63B 3.18B 2.99B 2.74B 5.11B 348B 5.15B 35.95B 13.94B 177B 13.62B 13.32B 574B P/E 2022
-48.9x
P/E 2023 -502x
Enterprise Value 3.31B 2.91B 2.73B 2.5B 4.67B 317B 4.7B 32.81B 12.72B 162B 12.43B 12.16B 524B EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
3 years 48.3
Extreme 48.3
71.05
5 years 38.41
Extreme 38.41
79.92
10 years 11.95
Extreme 11.95
79.92
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 30/09/2013
Director of Finance/CFO 41 01/10/2023
Chief Operating Officer 47 31/07/2018
Director TitleAgeSince
Director/Board Member 69 31/01/2018
Director/Board Member 74 07/04/2019
Date Insider Type Main position Quantity % Market Cap. Importance
15/11/24 Issuer sale

Executive/Senior Manager

59,355 0.1161%
15/11/24 Issuer sale

Responsable ventes & marketing

109,664 0.2145%
15/11/24 Issuer sale

Chief Technology Officer

63,237 0.1237%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%-.--%-.--%+29.29% 3.63B
-0.61%-3.99%-26.80%-4.16% 105B
-2.23%-3.31%-25.26%-2.99% 11.24B
-3.98%-6.11%+81.24%+103.89% 9.05B
+0.13%+5.21%-48.06%-66.10% 4.2B
+2.83%+7.86%-20.43%+30.25% 2.51B
-3.14%-5.07%-10.36%-62.67% 2B
+1.25%+10.10% - - 2.01B
+0.77%+2.25%-18.76%-26.45% 1.55B
Average -0.47%+0.68%-8.55%+0.13% 15.67B
Weighted average by Cap. -0.83%-3.24%-19.15%+1.50%

Financials

2022 2023
Net sales 274M 240M 226M 206M 386M 26.22B 389M 2.71B 1.05B 13.37B 1.03B 1.01B 43.34B 366M 322M 302M 276M 516M 35.1B 520M 3.63B 1.41B 17.89B 1.38B 1.35B 58.01B
Net income -59.7M -52.4M -49.25M -45.03M -84.15M -5.72B -84.77M -592M -229M -2.92B -224M -219M -9.45B -6.09M -5.34M -5.02M -4.59M -8.58M -583M -8.64M -60.33M -23.39M -297M -22.86M -22.36M -964M
Net Debt -348M -306M -287M -263M -491M -33.34B -494M -3.45B -1.34B -17B -1.31B -1.28B -55.12B -317M -279M -262M -239M -447M -30.4B -451M -3.14B -1.22B -15.5B -1.19B -1.17B -50.25B
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
797
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. AXNX Stock